# Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

> **NCT05010460** · PHASE2 · TERMINATED · sponsor: **Peking Union Medical College Hospital** · enrollment: 98 (actual)

## Conditions studied

- Coronary Artery Bypass

## Interventions

- **DRUG:** Roxadustat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05010460
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-30
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** slow enrollment and inability to reach the planned sample size within the expected timeframe
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010460, "Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05010460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*